Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.22
(-3.17%)
HKD 1.22
(-3.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 109.82 Million HKD | -60.14% |
| 2022 | 229.05 Million HKD | 88.49% |
| 2021 | 2.12 Billion HKD | -48.01% |
| 2020 | 279.42 Million HKD | -16.99% |
| 2019 | 235.54 Million HKD | -34.69% |
| 2018 | 516.17 Million HKD | 63.71% |
| 2017 | 319.99 Million HKD | -11.62% |
| 2016 | 332.13 Million HKD | 38.34% |
| 2015 | 301.04 Million HKD | -3.24% |
| 2014 | 259.71 Million HKD | 37.94% |
| 2013 | 194.44 Million HKD | 30.55% |
| 2012 | 148.71 Million HKD | 44.45% |
| 2011 | 109.73 Million HKD | 35.13% |
| 2010 | 76.41 Million HKD | 30.14% |
| 2009 | 58.57 Million HKD | 70.38% |
| 2008 | 34.43 Million HKD | 111.19% |
| 2007 | 16.4 Million HKD | 1437.91% |
| 2006 | -294 Thousand HKD | -245.45% |
| 2005 | 836 Thousand HKD | 162.62% |
| 2004 | -1.33 Million HKD | 61.77% |
| 2003 | -3.49 Million HKD | -14.53% |
| 2002 | -3.04 Million HKD | -138.95% |
| 2001 | -1.27 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | 10.23 Million HKD | 0.0% |
| 2023 Q2 | 55.07 Million HKD | 0.0% |
| 2023 Q1 | 55.07 Million HKD | 369.81% |
| 2023 FY | - HKD | -60.14% |
| 2023 Q3 | 10.23 Million HKD | -81.42% |
| 2022 Q4 | 11.72 Million HKD | -78.97% |
| 2022 Q1 | 35.24 Million HKD | 101.64% |
| 2022 Q2 | 16.11 Million HKD | -54.28% |
| 2022 Q3 | 55.74 Million HKD | 245.94% |
| 2022 FY | - HKD | 88.49% |
| 2021 Q2 | 2.09 Billion HKD | 4546.02% |
| 2021 Q4 | -2.15 Billion HKD | -19320.43% |
| 2021 FY | - HKD | -48.01% |
| 2021 Q3 | 11.19 Million HKD | -99.47% |
| 2021 Q1 | 45.1 Million HKD | -33.2% |
| 2020 FY | - HKD | -16.99% |
| 2020 Q1 | 46.97 Million HKD | -23.4% |
| 2020 Q2 | 20.62 Million HKD | -56.1% |
| 2020 Q3 | 17.97 Million HKD | -12.82% |
| 2020 Q4 | 67.51 Million HKD | 275.56% |
| 2019 FY | - HKD | -34.69% |
| 2019 Q3 | 41.99 Million HKD | 215.58% |
| 2019 Q4 | 61.32 Million HKD | 46.01% |
| 2019 Q1 | 61.66 Million HKD | -70.66% |
| 2019 Q2 | -36.33 Million HKD | -158.93% |
| 2018 Q4 | 210.18 Million HKD | 156.87% |
| 2018 Q2 | 71.55 Million HKD | -13.39% |
| 2018 Q1 | 82.62 Million HKD | 17.53% |
| 2018 FY | - HKD | 63.71% |
| 2018 Q3 | 81.82 Million HKD | 14.35% |
| 2017 Q2 | 58.91 Million HKD | 12.47% |
| 2017 Q1 | 52.38 Million HKD | -24.38% |
| 2017 FY | - HKD | -11.62% |
| 2017 Q3 | 74.14 Million HKD | 25.85% |
| 2017 Q4 | 70.29 Million HKD | -5.19% |
| 2016 Q4 | 69.26 Million HKD | -25.4% |
| 2016 Q3 | 92.84 Million HKD | 11.47% |
| 2016 Q1 | 60.21 Million HKD | -9.07% |
| 2016 Q2 | 83.29 Million HKD | 38.33% |
| 2016 FY | - HKD | 38.34% |
| 2015 FY | - HKD | -3.24% |
| 2015 Q3 | 68.2 Million HKD | 86.48% |
| 2015 Q2 | 36.57 Million HKD | -16.17% |
| 2015 Q1 | 43.63 Million HKD | -35.53% |
| 2015 Q4 | 66.21 Million HKD | -2.92% |
| 2014 Q2 | 51.56 Million HKD | 0.67% |
| 2014 Q3 | 60.14 Million HKD | 16.65% |
| 2014 Q4 | 67.67 Million HKD | 12.51% |
| 2014 FY | - HKD | 37.94% |
| 2014 Q1 | 51.22 Million HKD | 12.39% |
| 2013 Q2 | 48.85 Million HKD | 28.28% |
| 2013 Q3 | 45.12 Million HKD | -7.63% |
| 2013 Q4 | 45.57 Million HKD | 0.99% |
| 2013 FY | - HKD | 30.55% |
| 2013 Q1 | 38.08 Million HKD | 11.02% |
| 2012 FY | - HKD | 44.45% |
| 2012 Q3 | 36.06 Million HKD | 3.52% |
| 2012 Q1 | 28.98 Million HKD | -10.36% |
| 2012 Q2 | 34.84 Million HKD | 20.19% |
| 2012 Q4 | 34.3 Million HKD | -4.89% |
| 2011 Q1 | 19.06 Million HKD | 0.0% |
| 2011 Q4 | 32.34 Million HKD | 16.29% |
| 2011 FY | - HKD | 35.13% |
| 2011 Q2 | 19.18 Million HKD | 0.59% |
| 2011 Q3 | 27.81 Million HKD | 44.99% |
| 2010 FY | - HKD | 30.14% |
| 2010 Q2 | 18.63 Million HKD | 0.0% |
| 2009 Q2 | 13.75 Million HKD | 0.0% |
| 2009 FY | - HKD | 70.38% |
| 2008 FY | - HKD | 111.19% |
| 2007 FY | - HKD | 1437.91% |
| 2006 FY | - HKD | -245.45% |
| 2005 FY | - HKD | 162.62% |
| 2004 FY | - HKD | 61.77% |
| 2003 FY | - HKD | -14.53% |
| 2002 FY | - HKD | -138.95% |
| 2001 FY | - HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 26.981% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 96.298% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 184.79% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 3.496% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 318.639% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 73.751% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -43.306% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 519.657% |
| SSY Group Limited | 2.11 Billion HKD | 94.806% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 46.269% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 74.456% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.288% |